Personality disorders (PDs) are a category of DSM-5 mental disorders characterized by enduring patterns of inner experience and behaviour that deviate markedly from cultural expectations, are pervasive and inflexible, have onset in adolescence or early adulthood, are stable over time, and lead to distress or impairment. Borderline Personality Disorder (BPD) is the most clinically discussed PD in the psychedelic-assisted therapy literature, with Canadian lifetime prevalence estimated at ~1.4–5.9% depending on assessment method. This article is a safety-focused Canadian guide to why personality disorders — and BPD in particular — require careful clinical framing when evaluating psychedelic-assisted therapy: the foundational treatments for BPD remain DBT, MBT, TFP, and schema therapy; most psychedelic RCTs explicitly exclude personality-disorder primary patients; emerging signal exists for MDMA-assisted therapy in comorbid PTSD with BPD features, and off-label ketamine has limited but real-world use for BPD with comorbid TRD. Comprehensive PD assessment, suicidality risk management, and coordination with foundational PD treatments are non-negotiable.

Key takeaways

Personality disorders are DSM-5 enduring patterns of inner experience and behaviour. Three clusters: A (paranoid, schizoid, schizotypal), B (borderline, narcissistic, histrionic, antisocial), C (avoidant, dependent, OCPD).

BPD prevalence in Canada: ~1.4–5.9% lifetime depending on assessment method. The most clinically discussed PD in psychedelic-assisted therapy literature.

DBT (Dialectical Behavior Therapy — Linehan), MBT (Mentalization-Based Treatment — Bateman/Fonagy), TFP (Transference-Focused Psychotherapy — Yeomans/Clarkin/Kernberg), and schema therapy (Young) are the foundational evidence-based treatments for BPD. These are not optional adjuncts — they are the standard of care.

Most psychedelic RCTs EXCLUDE personality disorder primary patients — Goodwin 2022 COMP001, Mitchell 2021/2023 MDMA-AT, Carhart-Harris 2021 all excluded primary BPD or other PD diagnoses.

Off-label ketamine in PD: limited evidence; some real-world use in BPD with comorbid treatment-resistant depression with foundational DBT/MBT in place.

MDMA-AT for PTSD with comorbid BPD features: emerging signal in real-world and post-hoc analyses; BPD as primary indication is not RCT-validated.

Psilocybin and PD: investigational; PD-specific safety considerations include identity disturbance, dissociation, and emotion-regulation challenges during dosing.

Risk of destabilization, increased suicidality during/after psychedelic experiences without comprehensive support is the central safety concern.

ATMA CENA's clinical pathway: most PD patients route to DBT/MBT/TFP first; comorbid TRD/PTSD with stable PD treatment may be candidates for psychedelic-assisted therapy adjunct.

Defining personality disorders

DSM-5 personality disorders are organized into three clusters based on descriptive similarities:

Cluster A — odd or eccentric:

Paranoid Personality Disorder: pervasive distrust and suspiciousness
Schizoid Personality Disorder: detachment from social relationships; restricted emotional expression
Schizotypal Personality Disorder: discomfort in close relationships; cognitive/perceptual distortions; eccentricities

Cluster B — dramatic, emotional, or erratic:

Borderline Personality Disorder (BPD): instability of interpersonal relationships, self-image, affect; marked impulsivity; recurrent suicidality
Narcissistic Personality Disorder (NPD): grandiosity; need for admiration; lack of empathy
Histrionic Personality Disorder: excessive emotionality and attention-seeking
Antisocial Personality Disorder (ASPD): disregard for and violation of the rights of others

Cluster C — anxious or fearful:

Avoidant Personality Disorder: social inhibition; feelings of inadequacy
Dependent Personality Disorder: pervasive psychological dependence on other people
Obsessive-Compulsive Personality Disorder (OCPD): preoccupation with orderliness, perfectionism, and control (distinct from OCD)

PD diagnosis requires assessment by a qualified mental health professional and should not be made on the basis of a single clinical encounter or self-assessment.

Borderline Personality Disorder (BPD) — clinical specifics

BPD is the most clinically researched PD in the psychedelic-assisted therapy literature and the most common PD presentation seeking psychedelic-assisted therapy.

Core BPD features (DSM-5):

Emotion dysregulation: intense, rapidly shifting affect; difficulty returning to baseline
Identity disturbance: unstable self-image and sense of self
Interpersonal instability: alternation between idealization and devaluation
Impulsivity: in domains potentially self-damaging (spending, sex, substance use, reckless driving, binge eating)
Recurrent suicidal behaviour, gestures, threats, or self-mutilating behaviour
Chronic emptiness
Inappropriate, intense anger
Transient, stress-related paranoid ideation or severe dissociative symptoms

Suicidality: BPD is associated with substantially elevated suicide risk — up to ~10% lifetime suicide rate in some samples — making safety planning and suicidality risk management foundational to any treatment intervention.

Comorbidity: BPD has high comorbidity with PTSD, major depressive disorder, substance-use disorders, eating disorders, anxiety disorders, and bipolar disorder. Trauma history (particularly developmental trauma) is very common — making trauma-informed care essential for any clinical intervention, including psychedelic-assisted therapy.

Foundational evidence-based treatments for BPD

The PD field has well-established psychotherapy modalities with substantial RCT evidence — particularly for BPD. These are not optional adjuncts to psychedelic-assisted therapy; they are the standard of care that any psychedelic-assisted intervention must be coordinated with or follow.

DBT (Dialectical Behavior Therapy — Linehan)

Developed by Marsha Linehan at the University of Washington in the late 1980s. DBT integrates cognitive-behavioural techniques with mindfulness and dialectical philosophy. The standard DBT package includes weekly individual therapy, weekly skills group, between-session phone coaching, and therapist consultation team. DBT has the strongest RCT evidence base of any BPD treatment, with reductions in suicidal behaviour, self-harm, and treatment dropout demonstrated across multiple trials (Linehan 1991, 2006, 2015).

MBT (Mentalization-Based Treatment — Bateman/Fonagy)

Developed by Anthony Bateman and Peter Fonagy in the UK. MBT focuses on improving the patient's capacity to understand mental states (their own and others') — the capacity for "mentalization." Standard MBT is delivered as combined individual and group therapy over 12–18 months. RCT evidence (Bateman & Fonagy 1999, 2009) demonstrates reductions in self-harm, suicide attempts, and hospital admissions.

TFP (Transference-Focused Psychotherapy — Yeomans/Clarkin/Kernberg)

Developed by Frank Yeomans, John Clarkin, and Otto Kernberg. TFP is a psychodynamic treatment focused on integrating split self/object representations through the analysis of the transference relationship. RCT evidence (Clarkin 2007; Doering 2010) supports TFP for BPD, with comparable outcomes to DBT on several measures.

Schema therapy (Young)

Developed by Jeffrey Young. Schema therapy integrates cognitive-behavioural, psychodynamic, attachment, and gestalt approaches to address early maladaptive schemas. RCT evidence (Giesen-Bloo 2006) supports schema therapy for BPD.

For a comprehensive PD treatment landscape, foundational DBT/MBT/TFP/schema therapy is the standard of care — and generally precedes any consideration of psychedelic-assisted therapy adjuncts.

The PD evidence map for psychedelic-assisted therapy

Primary PD indication — generally not RCT-supported

Most psychedelic RCTs explicitly exclude personality disorder primary patients:

Goodwin 2022 COMP001 TRD trial: BPD and other PDs excluded
Carhart-Harris 2021 NEJM MDD trial: BPD excluded
Mitchell 2021/2023 MAPP1/MAPP2 PTSD trials: BPD excluded as primary indication (though comorbid BPD features were not always exclusionary)
Mithoefer 2018 MDMA-AT pilot: PD as primary indication excluded

Reasons for exclusion include: identity disturbance and dissociation risks, emotion dysregulation during dosing, suicidality risk, interpersonal instability with the therapy team, and research safety concerns about destabilization in this population.

Off-label ketamine in BPD — limited evidence

Limited RCT evidence specifically for BPD as primary indication
Real-world Canadian use: ketamine has been used in carefully-screened BPD patients with comorbid treatment-resistant depression when foundational DBT or MBT is in place
Mechanism considerations: glutamatergic mechanism; rapid antidepressant effect may benefit comorbid TRD without specifically targeting PD pathology
Suicidality: ketamine has demonstrated rapid suicidal-ideation reduction in TRD populations; this is potentially relevant to BPD with comorbid TRD but does not replace comprehensive safety planning

MDMA-AT for PTSD with comorbid BPD — emerging signal

Mitchell 2021/2023 MAPP1/MAPP2 primary indication is severe PTSD; comorbid BPD features were assessed in some participants
Post-hoc and real-world signal: emerging reports of meaningful PTSD symptom reduction in patients with PTSD and comorbid BPD features, particularly when trauma is a central driver
BPD as primary indication is not RCT-validated
Trauma-informed framing: developmental-trauma-driven BPD presentations may overlap meaningfully with complex PTSD; clinical formulation matters

Psilocybin and PD — investigational, safety considerations

PD primary indication not RCT-supported; psilocybin RCTs (Goodwin 2022, Carhart-Harris 2021) excluded PD
PD-specific safety considerations: identity disturbance risk during dosing; dissociation; emotion-regulation challenges; potential for destabilization without robust integration support
SAP applications for PD primary indication would face significant clinical resistance

Spravato and PD

The Health Canada Spravato product monograph indication is TRD; Spravato in BPD with comorbid TRD is off-label and clinical decision-making should weigh foundational PD treatment status

Decision framework — PD-specific considerations

For PD patients (especially BPD) considering psychedelic-assisted therapy:

Step	Question	Consequence
1	Is PD diagnosis confirmed by qualified mental health professional?	If unclear/never assessed: comprehensive PD assessment first
2	Is foundational PD treatment (DBT, MBT, TFP, schema therapy) established?	If no: foundational PD treatment initiation first
3	Is the primary indication PD itself, or comorbid TRD / PTSD with stable PD treatment?	PD primary indication: generally not appropriate. Comorbid TRD/PTSD with stable PD treatment: case-by-case
4	Is patient currently in acute crisis (suicidality, self-harm, dissociative episode)?	If yes: psychedelic-assisted therapy contraindicated; acute psychiatric care first
5	Is suicidality risk being actively managed with safety planning?	Required as a foundation
6	Is trauma history being addressed in trauma-informed care?	Trauma-informed framing is essential
7	Is there a stable therapeutic alliance with a PD-experienced clinician for integration?	Required

Canadian access pathways

Foundational PD treatment first

DBT programs: provincial mental health systems offer publicly-funded DBT in many regions; private DBT programs available across Canada
MBT and TFP: smaller availability than DBT; concentrated in academic medical centres
Schema therapy: private practice availability across Canada
Psychiatric coordination: BPD typically benefits from psychiatric specialist relationship; medication for comorbid mood/anxiety may be useful adjunct

Off-label ketamine for BPD with comorbid TRD

Out-of-pocket dominantly: ~$400–$1,500/session
Foundational PD treatment required: not a candidate for off-label ketamine without DBT/MBT/TFP/schema therapy in place and stable PD-experienced clinician relationship
Comprehensive PD assessment required: confirmation of PD diagnosis and treatment status

MDMA-AT for PTSD with comorbid BPD features

SAP-only pathway: no Health Canada approval; case-by-case Health Canada SAP applications for severe treatment-resistant PTSD where comorbid BPD features are present
Foundational PD treatment required: stable DBT/MBT or equivalent
Comprehensive trauma-informed assessment required

Psilocybin SAP for PD

Generally not recommended for PD primary indications
Case-by-case Health Canada SAP applications would require comprehensive assessment, foundational PD treatment, and PD-experienced psychiatric oversight

What the evidence does NOT say

No psychedelic-assisted therapy is approved or RCT-validated for personality disorders as a primary indication in Canada.
DBT, MBT, TFP, and schema therapy remain the foundational evidence-based treatments for BPD. Psychedelic-assisted therapy does not replace these.
Real-world ketamine use in BPD with comorbid TRD does not generalize to all PD populations. Other PD presentations (Cluster A, antisocial, narcissistic) have different clinical considerations.
MDMA-AT signal in comorbid PTSD+BPD does not validate BPD as a primary MDMA-AT indication. MDMA-AT remains investigational for PTSD primary indication.
Suicidality risk management is foundational. PD presentations — particularly BPD — carry elevated suicide risk; psychedelic-assisted therapy without comprehensive safety planning and PD-experienced clinical oversight is unsafe.
Destabilization risk is real. Identity disturbance, dissociation, emotion dysregulation, and interpersonal instability can be triggered or worsened by psychedelic experiences without comprehensive support.
Trauma-informed care is essential given high comorbid trauma history in PD populations.

How ATMA CENA works with PD patients

ATMA CENA's PD-specific pathway:

Comprehensive intake: explicit PD screening; foundational PD treatment status (DBT/MBT/TFP/schema therapy); trauma history; comorbid PTSD/TRD/SUD assessment; suicidality risk assessment
Foundational PD treatment first: ATMA CENA routes most PD patients to DBT/MBT/TFP/schema therapy as the foundational evidence-based treatment — psychedelic-assisted therapy is not a substitute
Comorbid TRD/PTSD pathway: BPD patients with comorbid treatment-resistant depression and stable foundational PD treatment may be candidates for off-label ketamine adjunct on a case-by-case basis
Comorbid PTSD pathway: BPD patients with severe treatment-resistant PTSD and stable foundational PD treatment may be candidates for case-by-case Health Canada SAP MDMA-AT application
No psilocybin/MDMA for PD primary indication: ATMA CENA does not support psilocybin or MDMA SAP applications for PD primary indications given safety considerations
Psychiatric coordination: PD patients require ongoing psychiatric specialist or PD-experienced therapist relationship; ATMA CENA will not work with PD patients without confirmed foundational PD treatment and clinical oversight
Honest framing: ATMA CENA is direct about what the evidence does and does not support; PD is complex and most clinical pathways will route to foundational PD treatment first

For more detail see Ketamine Therapy in Canada and MDMA-Assisted Therapy in Canada.

Frequently asked questions

Can I do psychedelic-assisted therapy if I have BPD? It depends. PD as a primary indication is generally not appropriate for current psychedelic-assisted therapy options — the RCT evidence excludes PD primary patients. However, BPD with comorbid treatment-resistant depression or treatment-resistant PTSD, with foundational DBT/MBT/TFP/schema therapy in place, may be a candidate for off-label ketamine (TRD) or case-by-case SAP MDMA-AT (PTSD). Comprehensive PD assessment is essential.

Can I do ketamine therapy if I have BPD? Possibly — but only with comprehensive PD assessment, established foundational PD treatment (DBT, MBT, TFP, or schema therapy), and PD-experienced clinical oversight. Off-label ketamine for BPD with comorbid TRD has limited but real-world Canadian use; BPD as primary indication is not RCT-validated.

Can I do MDMA-AT if I have BPD? Generally only in the context of severe treatment-resistant PTSD with comorbid BPD features, with foundational PD treatment in place, via case-by-case Health Canada SAP application. BPD as primary indication is not RCT-validated.

Can I do psilocybin therapy if I have BPD? Generally no for BPD primary indication. Psilocybin RCTs (Goodwin 2022, Carhart-Harris 2021) exclude PD patients. PD-specific safety concerns (identity disturbance, dissociation, emotion dysregulation, suicidality risk) are significant.

What is DBT and why does ATMA CENA require foundational PD treatment first? DBT (Dialectical Behavior Therapy) was developed by Marsha Linehan and has the strongest RCT evidence base of any BPD treatment, with demonstrated reductions in suicidal behaviour, self-harm, and treatment dropout. DBT, along with MBT, TFP, and schema therapy, is the standard of care for BPD. Psychedelic-assisted therapy does not replace these foundational treatments — it can only ever be considered as a possible adjunct for specific comorbidities, with foundational PD treatment in place.

What if I have BPD and active suicidality? Acute suicidality requires comprehensive psychiatric care and safety planning before any consideration of psychedelic-assisted therapy. Hospital evaluation may be appropriate. DBT crisis-line coaching, MBT crisis support, or equivalent foundational PD treatment crisis pathways should be in place.

What about complex PTSD vs BPD? Complex PTSD and BPD have meaningful clinical overlap, particularly when developmental trauma is a central driver. Trauma-informed clinical formulation matters. MDMA-AT signal in PTSD with comorbid BPD features is emerging but BPD as primary indication is not RCT-validated.

What about other PDs — Cluster A, Cluster C, antisocial, narcissistic? These PD presentations have different clinical considerations. Cluster A (particularly schizotypal) raises specific concerns about psychotic-spectrum vulnerability and is typically a contraindication for psilocybin/MDMA. Antisocial PD raises specific concerns about clinical alliance and integration. Cluster C presentations (avoidant, dependent, OCPD) are less commonly evaluated. Comprehensive PD assessment is essential for any PD presentation considering psychedelic-assisted therapy.

Can I share my PD diagnosis honestly with the clinical team? Yes — please do. PD history is critical clinical information; honest disclosure protects you. ATMA CENA's clinical team is non-judgmental and uses PD history to make appropriate clinical decisions, not to deny care reflexively.

What if I think I have BPD but have never been formally diagnosed? Comprehensive PD assessment by a qualified mental health professional is the appropriate first step. Self-assessment is not sufficient. ATMA CENA's clinical team can support referral pathways for comprehensive PD assessment.

Sources

Linehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL. (1991). Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry, 48(12):1060-4. PMID: 1845222.
Linehan MM, Comtois KA, Murray AM, et al. (2006). Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry, 63(7):757-66. PMID: 16818865.
Bateman A, Fonagy P. (1999). Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. Am J Psychiatry, 156(10):1563-9. PMID: 10518167.
Bateman A, Fonagy P. (2009). Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Am J Psychiatry, 166(12):1355-64. PMID: 19833787.
Clarkin JF, Levy KN, Lenzenweger MF, Kernberg OF. (2007). Evaluating three treatments for borderline personality disorder: a multiwave study. Am J Psychiatry, 164(6):922-8. PMID: 17541052.
Doering S, Hörz S, Rentrop M, et al. (2010). Transference-focused psychotherapy v. treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. Br J Psychiatry, 196(5):389-95. PMID: 20435966.
Giesen-Bloo J, van Dyck R, Spinhoven P, et al. (2006). Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Arch Gen Psychiatry, 63(6):649-58. PMID: 16754838.
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Personality Disorders chapter.
Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
Carhart-Harris R, Giribaldi B, Watts R, et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15):1402-1411. PMID: 33852780.
Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
Public Health Agency of Canada — Mental Illness Surveillance: https://health-infobase.canada.ca/mental-illness/

Last updated: 2026-05-06

Personality Disorders (BPD) and Psychedelic-Assisted Therapy — Considerations